MSK-IMPACT 468 (IMPACT468)

Overview

Targeted (468 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers — canonical cBioPortal gene panel IMPACT468.

Used by

  • PMID:36357680 — MSK patients in the NSCLC ctDNA cohort received tissue sequencing with MSK-IMPACT alongside ctDx Lung / MSK-ACCESS plasma assays; both MSK assays use matched WBC sequencing to remove clonal hematopoiesis and germline variants. Turnaround was 33 days (IQR 25–41) for MSK-IMPACT vs 11 days for the plasma assays PMID:36357680.
  • PMID:37078708 — used (alongside earlier panel versions) to profile 132 PTCL cases; TET2 (52%), RHOA (30%), DNMT3A (19%), TP53 (16%), and IDH2 (11%) were the most frequently mutated genes PMID:37078708.
  • PMID:37591896 — one of the MSK-IMPACT panel versions used for the 233-patient NSCLC brain metastasis cohort PMID:37591896.
  • PMID:39289779 — IMPACT468 was used to profile 274 CSF samples (earlier cohort) in a 1,007-sample CSF ctDNA study at MSK covering >90 CNS tumor types; genetic alterations were detected in 53% of CSF samples from patients with clinically documented CNS tumors PMID:39289779.
  • PMID:39214094 — IMPACT468 was the primary panel generation (n=1,536 of 2,336 patients) in a study of allele-specific KRAS biology in 397 resected PDAC patients at MSK; profiled alongside IMPACT341 and IMPACT410 for KRAS allele-specific analysis PMID:39214094.
  • PMID:39746944 — IMPACT468 provided the microsatellite locus list (1,755 loci generated by msisensor scan v0.2) used to train and validate the MiMSI deep MIL classifier for MSI detection; typical mean coverage ~600×, with downsampling to 100–400× for MiMSI vector inputs; IMPACT468 also anchored the 45,112-sample global concordance analysis PMID:39746944.
  • PMID:39753968 — IMPACT468 was the most commonly used panel (n=1,536 of 2,336 patients) in the MSK PDAC cohort; allele-specific copy number from FACETS used to identify KRAS mutant-allele dosage gains as an independent negative prognostic marker across clinical stages PMID:39753968.
  • 468-gene MSK-IMPACT panel applied to 42 treatment-naive HGSOC patients in MSK SPECTRUM cohort; complemented WGS mutational signature classification and scRNA-seq immune profiling PMID:36517593
  • 468-gene version of MSK-IMPACT applied to a subset of 295 metastatic EGC patients; the largest panel used in this study PMID:29122777
  • Used in 9 of 1,134 prospectively sequenced COADREAD cases in the MSK-IMPACT CRC landscape study; latest panel expansion PMID:29316426
  • Applied to 20 of 240 advanced NSCLC patients treated with anti-PD-(L)1 therapy in the MSK TMB study; panel was noted as the reference for 240-patient cohort TMB estimation PMID:29337640

Notes

  • The 468-gene panel succeeded IMPACT410 and is broadly used across MSK clinical sequencing cohorts PMID:36357680.

Sources

This page was processed by crosslinker on 2026-05-05. - PMID:36517593

This page was processed by crosslinker on 2026-05-05. - PMID:29122777

This page was processed by entity-page-writer on 2026-05-15. - PMID:29316426

This page was processed by wiki-cli on 2026-05-15. - PMID:29337640

This page was processed by wiki-cli on 2026-05-15.